A recent retrospective analysis of epithelial ovarian cancer patients receiving ICB immunotherapy of targets including PD-1, PD-L1, CTLA-4, and LAG-3 alone or in combination, found that over 50% of patients suffer disease progression requiring early discontinuation of therapy [302]. Here, CTLA4 is linked to ovarian carcinoma.